Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis.
Adult
Antibodies, Monoclonal, Humanized
/ pharmacology
Biomarkers
/ blood
Chronic Disease
Cytokines
/ analysis
Humans
Immunoglobulin E
/ analysis
Inflammation
/ prevention & control
Interleukin-13
/ antagonists & inhibitors
Interleukin-4
/ antagonists & inhibitors
Male
Middle Aged
Nasal Polyps
Rhinitis
/ pathology
Sinusitis
/ complications
biomarkers
dupilumab
nasal polyposis
nasal secretions
type 2 inflammation
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
14
03
2018
revised:
20
09
2018
accepted:
08
10
2018
pubmed:
30
11
2018
medline:
6
5
2020
entrez:
30
11
2018
Statut:
ppublish
Résumé
Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a type 2-mediated inflammatory disease associated with significant clinical, social, and economic burdens and high unmet therapeutic need. Dupilumab, a fully human monoclonal antibody targeting the interleukin-4 receptor α (IL-4Rα) subunit, demonstrated efficacy and acceptable safety in CRSwNP and other type 2 diseases (eg, atopic dermatitis and asthma). We now report the local effects of dupilumab on type 2 inflammatory biomarkers in nasal secretions and nasal polyp tissues of patients with CRSwNP in a randomized, placebo-controlled, phase 2 trial (NCT01920893). Cytokines, chemokines, and total immunoglobulin E (IgE) levels were measured using immunoassay techniques in nasal secretions and nasal polyp tissue homogenates of CRSwNP patients receiving dupilumab 300 mg or placebo weekly for 16 weeks. With dupilumab, type 2 biomarker concentrations decreased in nasal secretions (least squares mean area under the curve from 0 to 16 weeks for the change from baseline) vs placebo for eotaxin-3 (-30.06 vs -0.86 pg/mL; P = 0.0008) and total IgE (-7.90 vs -1.86 IU/mL; P = 0.022). Dupilumab treatment also decreased type 2 biomarker levels in nasal polyp tissues at Week 16 vs baseline for eosinophilic cationic protein (P = 0.008), eotaxin-2 (P = 0.008), eotaxin-3 (P = 0.031), pulmonary and activation-regulated chemokine (P = 0.016), IgE (P = 0.023), and IL-13 (P = 0.031). Dupilumab treatment reduced multiple biomarkers of type 2 inflammation in nasal secretions and polyp tissues of patients with CRSwNP, demonstrating that antagonism of IL-4Rα signaling suppresses IL-4-/IL-13-dependent processes, such as mucosal IgE formation, as well as the expression of chemokines attracting inflammatory cells to the nasal mucosa.
Sections du résumé
BACKGROUND
Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a type 2-mediated inflammatory disease associated with significant clinical, social, and economic burdens and high unmet therapeutic need. Dupilumab, a fully human monoclonal antibody targeting the interleukin-4 receptor α (IL-4Rα) subunit, demonstrated efficacy and acceptable safety in CRSwNP and other type 2 diseases (eg, atopic dermatitis and asthma). We now report the local effects of dupilumab on type 2 inflammatory biomarkers in nasal secretions and nasal polyp tissues of patients with CRSwNP in a randomized, placebo-controlled, phase 2 trial (NCT01920893).
METHODS
Cytokines, chemokines, and total immunoglobulin E (IgE) levels were measured using immunoassay techniques in nasal secretions and nasal polyp tissue homogenates of CRSwNP patients receiving dupilumab 300 mg or placebo weekly for 16 weeks.
RESULTS
With dupilumab, type 2 biomarker concentrations decreased in nasal secretions (least squares mean area under the curve from 0 to 16 weeks for the change from baseline) vs placebo for eotaxin-3 (-30.06 vs -0.86 pg/mL; P = 0.0008) and total IgE (-7.90 vs -1.86 IU/mL; P = 0.022). Dupilumab treatment also decreased type 2 biomarker levels in nasal polyp tissues at Week 16 vs baseline for eosinophilic cationic protein (P = 0.008), eotaxin-2 (P = 0.008), eotaxin-3 (P = 0.031), pulmonary and activation-regulated chemokine (P = 0.016), IgE (P = 0.023), and IL-13 (P = 0.031).
CONCLUSIONS
Dupilumab treatment reduced multiple biomarkers of type 2 inflammation in nasal secretions and polyp tissues of patients with CRSwNP, demonstrating that antagonism of IL-4Rα signaling suppresses IL-4-/IL-13-dependent processes, such as mucosal IgE formation, as well as the expression of chemokines attracting inflammatory cells to the nasal mucosa.
Identifiants
pubmed: 30488542
doi: 10.1111/all.13685
pmc: PMC6590149
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Biomarkers
0
Cytokines
0
IL4 protein, human
0
Interleukin-13
0
Interleukin-4
207137-56-2
Immunoglobulin E
37341-29-0
dupilumab
420K487FSG
Banques de données
ClinicalTrials.gov
['NCT01920893']
Types de publication
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
743-752Subventions
Organisme : Sanofi
Pays : International
Organisme : Regeneron Pharmaceuticals, Inc.
Pays : International
Informations de copyright
© 2018 The Authors. Allergy Published by John Wiley & Sons Ltd.
Références
J Allergy Clin Immunol. 2001 Apr;107(4):607-14
pubmed: 11295647
Am J Respir Crit Care Med. 2013 Aug 15;188(4):432-9
pubmed: 23805875
Thorax. 2011 Sep;66(9):824-5
pubmed: 21109700
Allergy. 2019 Apr;74(4):743-752
pubmed: 30488542
Am J Rhinol Allergy. 2014 May-Jun;28(3):192-8
pubmed: 24980230
Rhinology. 2012 Mar;50(1):1-12
pubmed: 22469599
N Engl J Med. 2016 Dec 15;375(24):2335-2348
pubmed: 27690741
Am J Respir Cell Mol Biol. 2001 Jun;24(6):682-7
pubmed: 11415932
Allergy. 2006 Nov;61(11):1280-9
pubmed: 17002703
J Clin Invest. 2008 Nov;118(11):3546-56
pubmed: 18982161
Lancet. 2017 Jun 10;389(10086):2287-2303
pubmed: 28478972
Respir Res. 2011 Jan 14;12:10
pubmed: 21235798
J Allergy Clin Immunol. 2014 Dec;134(6):1293-1300
pubmed: 25482871
Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5147-52
pubmed: 24706858
Curr Opin Immunol. 2002 Feb;14(1):129-35
pubmed: 11790543
Allergy. 2011 Sep;66(9):1216-23
pubmed: 21605125
J Allergy Clin Immunol. 2011 Nov;128(5):989-95.e1-8
pubmed: 21958585
N Engl J Med. 2018 Jun 28;378(26):2486-2496
pubmed: 29782217
J Allergy Clin Immunol. 2016 May;137(5):1449-1456.e4
pubmed: 26949058
Clin Exp Allergy. 2015 Feb;45(2):394-403
pubmed: 25429730
Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5153-8
pubmed: 24706856
J Allergy Clin Immunol. 2017 Oct;140(4):1024-1031.e14
pubmed: 28687232
Immunol Allergy Clin North Am. 2004 Nov;24(4):599-614, vi
pubmed: 15474861
Nat Rev Drug Discov. 2016 Jan;15(1):35-50
pubmed: 26471366
Curr Opin Allergy Clin Immunol. 2011 Apr;11(2):109-14
pubmed: 21301328
Rhinology. 2017 Jun 1;55(2):152-160
pubmed: 28501884
J Allergy Clin Immunol. 2011 Oct;128(4):728-32
pubmed: 21868076
J Allergy Clin Immunol. 2011 Jul;128(1):73-81.e4
pubmed: 21497884
Br J Dermatol. 2018 May;178(5):1083-1101
pubmed: 29193016
N Engl J Med. 2018 Jun 28;378(26):2475-2485
pubmed: 29782224
J Allergy Clin Immunol. 2012 Jan;129(1):119-27.e1-9
pubmed: 21943944
Clin Exp Allergy. 2007 Dec;37(12):1840-7
pubmed: 17941912
J Allergy Clin Immunol. 2008 Nov;122(5):961-8
pubmed: 18804271
J Allergy Clin Immunol. 2013 Apr;131(4):1075-83, 1083.e1-7
pubmed: 23473835
J Leukoc Biol. 2005 Jul;78(1):14-26
pubmed: 15784687
J Allergy Clin Immunol. 2015 Dec;136(6):1431-1440
pubmed: 26654192
Inflammation. 2016 Jun;39(3):1253-67
pubmed: 26861136
J Immunol. 1999 Mar 1;162(5):2477-87
pubmed: 10072486
Exp Mol Med. 2016 Jan 08;48(1):e202
pubmed: 27534531
J Allergy Clin Immunol. 2013 Jan;131(1):110-6.e1
pubmed: 23021878
J Clin Invest. 2006 Feb;116(2):536-47
pubmed: 16453027
Eur Arch Otorhinolaryngol. 2013 Sep;270(10):2667-76
pubmed: 23430080
Eur J Immunol. 2006 Oct;36(10):2700-14
pubmed: 16983721
Am J Rhinol. 2008 Mar-Apr;22(2):115-21
pubmed: 18416964
Expert Rev Clin Immunol. 2015 Mar;11(3):349-61
pubmed: 25651905
J Immunol. 2006 May 15;176(10):6286-93
pubmed: 16670340
JAMA. 2016 Feb 2;315(5):469-79
pubmed: 26836729
Rhinology. 2006 Jun;44(2):145-50
pubmed: 16792175